Effect of recombinant human erythropoietin treatment on renal anemia and body growth of children with end-stage renal disease. The European Multicenter Study Group.
Scigalla
P
P
Department of Clinical Research, Boehringer Mannheim GmbH, FRG.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000740:Anemia / Q000188:drug therapy*; D001827:Body Height / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006128:Growth / Q000187:drug effects*; D006400:Hematocrit; D006801:Humans; D007223:Infant; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000503:physiopathology; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin